Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Single or Combined Capecitabine in Metastatic Her-2 Negative Breast Cancer
NCT03086785Phase 2Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03086785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086785.